IP Library Granted Patent US 10,189,823
Granted Patent B2
US 10,189,823 · App. 15/841,749 · Granted Jan 29, 2019

Neprilysin inhibitors

Inventors: Melissa Fleury (Brisbane, CA); Adam D. Hughes (Half Moon Bay, CA)
Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
C07D405/12A61K31/415A61K31/4192A61K31/42A61K31/421A61K45/06C07D231/14C07D231/20C07D249/04C07D261/18C07D263/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,189,823
App. No.
15/841,749
Granted
Jan 29, 2019
Kind
B2
Abstract

In one aspect, the invention relates to compounds having the formula: where X, R a , R b , R 2 , and R 7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Claims (6)

1. A method for treating hypertension, the method comprising administering to patient a therapeutically effective amount of a compound of the following structure:

or a pharmaceutically acceptable salt thereof;

wherein the hypertension is selected from the group consisting of primary hypertension, secondary hypertension, hypertension with accompanying renal disease, severe hypertension with or without accompanying renal disease, pulmonary hypertension, and resistant hypertension.

2. The method according to claim 1 , wherein the hypertension is resistant hypertension.

3. A method for treating portal hypertension, the method comprising administering to patient a therapeutically effective amount of a compound of the following structure:

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: EONHF, INC.
Reel/Frame 075494/0756 →
Continuity (6)
Continuation 15497508 · Apr 26, 2017
Continuation 14812095 · Jul 29, 2015
Continuation 13961269 · Aug 7, 2013
Provisional Application 61774163 · Mar 7, 2013
Provisional Application 61680804 · Aug 8, 2012
Related Publication 20180237423A1 · Aug 23, 2018
Cited By (1)
US 12,351,561